Bone Marrow & Stem Cell Transplant

A GVHD expert outlines the treatments available for patients with chronic GVHD and steroid-refractory chronic GVHD.

Nelson J. Chao, MD, gives an overview of acute and chronic GVHD, and details the classical presentation and staging process.

An expert on graft-vs-host disease discusses allogeneic stem cell transplantation, and reviews transplant conditioning and GVHD prophylaxis regimens.

Nelson J. Chao, MD, presents a patient profile of a 35-year-old woman diagnosed with chronic graft-vs-host disease, and provides his initial thoughts.

In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed relapse after transplant for patients with cancer and what is important to note moving forward with research.

Robert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.

Closing out his discussion on chronic graft-vs-host disease, Yi-Bin Chen, MD, looks to the future of GVHD treatment.

Yi-Bin-Chen, MD, discusses the effect of GVHD recurrence and multiple-organ involvement on treatment decisions.

A summary of the systemic treatment options available for steroid-refractory chronic GVHD.

A comprehensive overview of the various treatment options for chronic graft-vs-host disease.

Yi-Bin Chen, MD, describes acute and chronic GVHD, and details the typical symptoms and presentations.

An expert on graft-vs-host disease provides an overview of GVHD prophylaxis and conditioning regimens prior to transplant.

Yi-Bin Chen, MD, an expert clinician and researcher, reviews a case study of a patient with GVHD and offers his initial impressions.

In an interview with Targeted Oncology, Lori Muffly, MD, discusses the subanalysis of a phase 1 study of briquilimab plus low-dose total body radiation and fludarabine which was presented at 2023 Tandem Meetings on Transplantation and Cellular Therapy.

In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the full data from the phase 2 trial of panobinostat, gemcitabine, busulfan, and melphalan for patients with high-risk, relapsed/refractory myeloma.

Samer A. Srour, MD, MS, discusses some of the takeaways from the dose-expansion phase of an ongoing phase 1 trial evaluating Orca-Q.

The phase 3 GRAPHITE study showed that vedolizumab plus standard prophylaxis after unrelated allogeneic hematopoietic stem cell transplantation was more effective vs placebo for the prevention of lower gastrointestinal graft-vs-host disease.

In findings from the phase 3 SIERRA trial, Iomab-B-based conditioning for patients with relapsed or refractory acute myeloid leukemia provided significant efficacy and tolerable safety results over the current standard of care.

Tisagenlecleucel reinfusion shows promise as as an effective bridge to hematopoietic stem cell transplantation in pediatric B-cell acute lymphoblastic leukemia.

Novel treatments are needed to replace transplant and prevent graft-vs-host disease in order to improve patient outcomes.

Long-term outcomes did not differ among de novo late acute graft-vs-host disease and classic acute graft-vs-host disease, showing they should be treated the same way.

Yago Nieto, MD, PhD, discusses the findings from a phase 2 trial evaluating treatment with panobinostat, gemcitabine, busulfan, and melphalan for high-risk or relapsed/refractory myeloma.

Regardless of prior therapies, brexucabtagene autoleucel showed a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, according to subgroup analyses of the phase 3 ZUMA-3 trial.

Risk of relapse was significantly greater for those with acute lymphoblastic leukemia who had low minimal residual disease of less than 10-4 vs those with undetectable MRD, according to results of a retrospective study.